Skip to main content

InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Receive First Payment on ‘Milestone’ Purchase of Cancer Detection Equipment

AnPac Bio-Medical Science (NASDAQ: ANPC), a company with operations in the United States and China focused on early cancer screening and detection, received the first payment in late February 2023 from a Malaysian customer that had purchased AnPac Bio’s Model AP9080 cancer detection devices. The contract for these devices totaled $1.5 million. According to the announcement, the proprietary Model AP9080 features ANPC’s Cancer Differentiation Analysis Technology (“CDA”), a patented, novel multicancer testing technology. Company representatives called the order a “milestone” because it is the first major sales of AnPac Bio’s cancer detection device in the southeast Asia region, representing the company’s entry into the global cancer detection equipment market and confirming AnPac Bio’s novel technology, reputation, and capabilities. “We are very pleased with this major milestone accomplishment,” said AnPac Bio-Medical Science co-CEO Dr. Chris Yu in the press release. “It showed that in addition to China and U.S., our novel cancer detection technology is also being recognized in other parts of Asia, which has significant market size and needs for general population based cancer screening and risk assessment. Due to our technology’s unique advantages (multicancer, cost effective, ability to detect early, and high sensitivity and specificity), our patented cancer detection technology is highly suited for the region. We expect significant revenue and growth potential in the region. We will also work very hard to replicate this success.”

To view the full press release, visit

About AnPac Bio-Medical Science Co. Ltd.

AnPac Bio is a biotechnology company focused on early cancer screening and detection, with 155 issued patents as of June 30, 2022. With two certified clinical laboratories in China and one CLIA- and CAP-accredited clinical laboratory in the United States, AnPac Bio performs a suite of cancer-screening and detection tests, including Cancer Differentiation Analysis (“CDA”), biochemical, immunological and genomics tests. The company intends to enter the business-to-business e-commerce food business with the acquisition of Fresh2 Ecommerce Inc. For more information about the company, visit

NOTE TO INVESTORS: The latest news and updates relating to ANPC are available in the company’s newsroom at

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published:

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office

InvestorWire is part of the InvestorBrandNetwork

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.